Lv5
1110 积分 2024-12-10 加入
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
25天前
已完结
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
25天前
已完结
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
25天前
已完结
Impact of Real-World Response to First-Line Immunotherapy and Chemotherapy on Subsequent Treatment Outcomes in Patients With Advanced or Metastatic Non–Small Cell Lung Cancer
28天前
已关闭
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
3个月前
已完结
Exact matching as an alternative to propensity score matching
5个月前
已完结
A Comparison of Two Methods for Adaptive Multi-Arm Two-Stage Design
6个月前
已完结
An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties
6个月前
已完结
Dose-response characterization: A key to success in drug development
6个月前
已完结
Informative event rate in study determination, study design, and interim analysis monitoring with non-proportional hazards
7个月前
已完结
皖公网安备34019202002308
